Congenital hypothyroidism is an endocrine condition present at birth, characterized by an inadequate availability of thyroid hormones to tissues during a critical stage of development, with potential consequences for growth, skeletal maturation and, above all, neurodevelopment. In most cases, the cause is a primary defect of the thyroid gland or of hormone biosynthesis, whereas a smaller proportion is related to central defects of the hypothalamic-pituitary-thyroid axis or to transient conditions that temporarily reduce the production or action of thyroid hormones. From a public health perspective, the distinguishing feature is that the disease is typically paucisymptomatic during the first weeks of life, but its most severe complications can be prevented through newborn screening and the early initiation of replacement therapy.
The clinical objective is not merely to “normalize” biochemical parameters, but to ensure rapid and stable cerebral and somatic exposure to adequate levels of levothyroxine, avoid diagnostic and therapeutic delays, and define the etiology when useful for prognosis, family counseling and long-term management. From a practical perspective, congenital hypothyroidism should be regarded as an endocrine emergency requiring low-intensity care but carrying extremely high prognostic relevance, because the timing and quality of replacement therapy during the first weeks substantially influence neurocognitive outcomes.
Congenital hypothyroidism is one of the most common endocrine disorders identified during the neonatal period through screening programs. The observed prevalence varies among countries and regions according to multiple determinants, including the sensitivity and specificity of screening cut-offs, TSH- and/or T4-based strategies, the timing of sample collection, the proportion of preterm and low-birth-weight infants, retesting policies, and the frequency of transient forms associated with environmental or maternal factors. Clinically, this variability means that the “true” estimate depends not only on the biological epidemiology of the disease, but also on the architecture of the screening system and the degree of attention devoted to identifying milder or delayed forms.
An important epidemiological determinant is the proportion of forms caused by thyroid dysgenesis compared with those caused by dyshormonogenesis. Dysgenesis includes agenesis, hypoplasia and ectopia and is sporadic in most cases, whereas forms caused by defects in hormone biosynthesis are more frequently familial, often with autosomal recessive inheritance, and may present with goiter due to TSH-dependent stimulation and substrate accumulation. Transient forms, including hypothyroidism caused by iodine excess or deficiency, exposure to medications or iodine-containing disinfectants, and maternal antibodies that block the TSH receptor, have a variable impact and may contribute significantly to the apparent increase in prevalence among populations with specific exposure patterns.
Among neonatal risk factors, prematurity and low birth weight play a particular role because they alter both thyroid physiology and test interpretation. Preterm infants frequently have greater instability of thyroid function, with the possibility of transient hypothyroxinemia, immaturity of the axis and an increased risk of conditions requiring closer follow-up and, in some cases, serial reassessment. Infants admitted to neonatal intensive care units also more frequently have screening results influenced by systemic illness, procedures, medications and nutrition, making a structured confirmation and monitoring pathway essential.
From the maternal perspective, autoimmune thyroid disorders may be relevant not only because of the risk of maternal thyroid dysfunction during pregnancy, but also because of the rare yet clinically important possibility of transplacental passage of antibodies that interfere with fetal and neonatal thyroid function. Exposure to iodine represents another key issue. Iodine excess may induce functional blockade of organification with transient hypothyroidism, whereas severe iodine deficiency is a historical and geographical risk factor for fetal hypothyroxinemia and hypothyroidism, with effects on neurodevelopment. Finally, certain maternal treatments, including antithyroid agents, may contribute to neonatal hypothyroidism when used during pregnancy, requiring specific attention during neonatal follow-up.
In summary, the epidemiology of congenital hypothyroidism is inseparable from the quality of screening and the presence of risk factors for transient forms or falsely abnormal results. Therefore, in addition to diagnosis, it is essential to establish a surveillance pathway for high-risk groups in order to avoid both unnecessary treatment and, above all, failure to identify cases requiring timely therapy.
Congenital hypothyroidism may result from a defect in thyroid structure, thyroid hormone synthesis and secretion, or central regulation. During neonatal physiology, the hypothalamic-pituitary-thyroid axis undergoes an immediate phase of adaptation after birth, characterized by a peak in TSH and an increase in T4 and T3 that support thermogenesis, metabolism and neurological maturation. Any significant interference during this window may reduce thyroid hormone availability precisely when the developing brain is highly dependent on thyroid signaling, particularly for neuronal migration, myelination and synaptogenesis. This is why the pathophysiology of congenital hypothyroidism is primarily a pathophysiology of timing. An early and prolonged deficiency carries a greater risk of unfavorable neurocognitive outcomes than a later deficiency or one that is rapidly corrected.
The most common causes include thyroid dysgenesis, in which the gland is absent, hypoplastic or ectopic because of errors in embryonic development and migration. In these forms, the capacity to produce hormones is intrinsically reduced and the condition is often permanent. Thyroid dysgenesis is largely sporadic, although genes involved in thyroid development may be implicated in a minority of cases, with consequences for familial recurrence and for the presence of associated phenotypes, including certain syndromic disorders in which thyroid abnormalities coexist with neurological or respiratory manifestations.
A second major group is represented by dyshormonogenesis, meaning defects in thyroid hormone biosynthesis. In these cases, the thyroid gland may be present and is often exposed to chronic TSH stimulation, resulting in the development of goiter. Defects may involve iodine transport and organification, thyroglobulin synthesis, iodotyrosine coupling and other enzymatic steps, producing reduced T4 and T3 synthesis despite a strong trophic signal. The pathophysiology is characterized by dissociation between pituitary stimulation and thyroid hormone output, with a compensatory excess of TSH that also becomes a driver of glandular growth.
Alongside permanent forms, there is a clinically relevant group of transient forms. Iodine excess during the perinatal period may induce functional blockade of organification, particularly in neonates whose ability to “escape” from the blockade is immature, causing hypothyroidism that may resolve when exposure ceases. In specific settings, iodine deficiency reduces the substrate available for hormone synthesis and may contribute to hypothyroidism or hypothyroxinemia. Maternal antibodies that block the TSH receptor or medications that reduce hormone synthesis may cause a transient but clinically significant condition, because risk depends not on the permanence of the cause, but on the duration of nervous system exposure to an uncorrected hormone deficiency.
A smaller proportion of cases is caused by congenital central hypothyroidism, in which the deficiency results from inadequate TSH secretion or defects upstream in hypothalamic regulation. This subgroup is particularly important because it may not be detected by screening programs based exclusively on TSH and is more frequently associated with multiple pituitary hormone deficiencies, with acute implications, particularly for the corticotropic axis. In these cases, the pathophysiology becomes that of multi-axis dysfunction, and management must ensure safety in the sequence of hormone replacement.
In summary, the logical sequence leading to disease is a structural or biochemical thyroid defect, or a central defect in stimulation, causing reduced T4 and T3 levels, decreased tissue availability of thyroid hormone and impairment of neurodevelopmental and somatic processes. The rationale for screening and early therapy derives directly from this causal chain and from the fact that damage can be prevented if exposure to the deficiency is rapidly reduced.
The clinical presentation of congenital hypothyroidism is often subtle during the first weeks of life, particularly in countries with effective screening, because diagnosis is established before marked signs appear. This does not mean that the disease is “benign”, but rather that early clinical expression is attenuated by maternally derived thyroid hormones and by the gradual manner in which the deficiency produces clinical signs. When present, manifestations tend to be nonspecific and are easily attributed to common neonatal conditions. Medical history and physical examination are therefore particularly useful for increasing clinical suspicion when screening is unavailable or delayed and for identifying more severe forms.
The medical history may reveal feeding difficulties, poor weight gain, drowsiness and reduced responsiveness. Prolonged jaundice, constipation and reduced cold tolerance may occur. In some neonates, the voice may sound hoarse and the cry may be weaker, while the infant may be described as “too quiet”, a clinical observation that, although nonspecific, becomes more significant when associated with compatible biochemical findings. In more severe untreated forms, progression may include impaired growth, delayed skeletal maturation and, over time, impairment of neuropsychomotor development.
Possible findings on physical examination include macroglossia, dry and cold skin, a hypomimic facial appearance and, in some forms, umbilical hernia. Muscle tone may be reduced and reflexes may show delayed relaxation, although neurological assessment during the neonatal period requires experience and appropriate clinical context. Goiter may be present in dyshormonogenesis or in conditions caused by iodine or medication exposure, but it is not a constant finding, and its absence does not exclude a severe permanent form, particularly thyroid dysgenesis.
In older children with a delayed diagnosis or forms that were not detected, the clinical picture tends to shift toward more typical signs of hypothyroidism, including impaired linear growth, relative weight gain, constipation, reduced school performance and drowsiness. Pubertal maturation may be variably affected, and multisystem manifestations may develop in the most severe cases. However, because the most significant consequences of congenital hypothyroidism are potentially preventable, late clinical presentation should be avoided through screening, rapid confirmation and effective clinical management.
The clinical assessment of a neonate with suspected or confirmed congenital hypothyroidism should therefore focus on reconstructing the timing of symptoms, evaluating signs of severity, identifying features suggestive of a specific etiology, such as goiter or associated abnormalities, and, above all, establishing without delay a pathway integrating biochemical confirmation, initiation of treatment and subsequent etiological definition when appropriate.
Congenital hypothyroidism should be suspected immediately when newborn screening is positive or borderline and requires confirmation. In this situation, the decisive factor is not the presence of symptoms, but the need to prevent prolonged exposure of the nervous system to thyroid hormone deficiency. Suspicion should also remain high in neonates in whom screening was not performed, was performed too early with a risk of uninterpretable results, or was performed but the result is not available within an appropriate timeframe, particularly when the neonate has compatible, even nonspecific, signs such as prolonged jaundice, marked drowsiness, feeding difficulties and constipation.
Preterm and critically ill neonates represent a particular setting in which suspicion must remain high because thyroid physiology is unstable and test results may be influenced by systemic illness. In these cases, a single result may be insufficient, and the safest strategy is often based on scheduled repeat testing and specialist interpretation. The clinical risk is twofold: failing to identify a form that requires early therapy or inappropriately treating a transient variation with no clinical relevance. The presence of risk factors for iodine or medication exposure further increases the need for caution and requires a detailed history of procedures and medications used during the perinatal period.
Suspicion should also remain high when there is a suggestive maternal history, such as autoimmune thyroid disease or the use of medications that interfere with thyroid function during pregnancy. In these cases, even when screening has been performed, the possibility of transient or atypical forms requires targeted follow-up. In addition, a family history of congenital hypothyroidism or childhood goiter may suggest genetic defects in hormone synthesis and strengthens the indication for a more complete diagnostic evaluation and counseling when appropriate.
Another scenario requiring particular attention is suspected congenital central hypothyroidism. When screening is based on TSH, a neonate with reduced FT4 and non-elevated TSH may not be identified. Suspicion should therefore arise in the presence of signs of pituitary dysfunction, such as recurrent hypoglycemia, micropenis or manifestations of multiple hormone deficiencies, because in this situation the clinical priority may also include the risk of adrenal insufficiency. The diagnostic reasoning must therefore consider the entire endocrine axis rather than the thyroid gland as an isolated organ.
In summary, every abnormal screening result requires rapid confirmation, and in the absence of screening, suspicion must be maintained when compatible clinical signs or risk settings for transient or central forms are present. The objective is to minimize the time between identification and biochemical correction, because the benefit of therapy is strictly time-dependent.
The diagnosis of congenital hypothyroidism is based on a pathway that begins with newborn screening and culminates in biochemical confirmation using a venous blood sample. Following a positive or suspicious screening result, the priority is to measure serum TSH and FT4, because the combination of these two parameters makes it possible to establish both the presence of hypothyroidism and, as an initial approximation, the severity of hormone deficiency. Reduced FT4 with elevated TSH confirms a primary form, whereas reduced FT4 with non-elevated TSH raises suspicion of a central form or of non-thyroidal conditions that affect interpretation. In all cases, timing is crucial. Confirmation must not delay the initiation of treatment when the biochemical pattern is compatible with clinically significant hypothyroidism.
Severity stratification is clinically useful because it guides the urgency and intensity of monitoring. Markedly reduced FT4 suggests a more severe form, often associated with dysgenesis or major defects in hormone synthesis, and requires rapid normalization of circulating levels through appropriate treatment. In milder or borderline forms, confirmation may require repeat testing and careful interpretation, particularly in preterm and critically ill neonates, in whom non-thyroidal illness syndrome and immaturity of the axis may produce transient abnormalities. In these settings, the diagnostic approach should be neither automatic nor excessively expectant, but should be guided by serial follow-up protocols designed to minimize the risk of missing clinically relevant cases.
Once treatment has been initiated, etiological assessment may be performed through second-level investigations when clinically appropriate and without interfering with therapy. Thyroid ultrasonography allows assessment of the presence, location and volume of the gland and identification of hypoplasia, agenesis or structural abnormalities. Thyroid scintigraphy using radioisotopes may help distinguish ectopia, agenesis and uptake defects and characterize certain forms of dyshormonogenesis. In selected settings, functional tests such as the perchlorate discharge test may support the hypothesis of defects in iodine organification, although their use depends on availability, local protocols and clinical objectives.
Measurement of thyroglobulin may provide indirect information about the presence of thyroid tissue, while a history of iodine or medication exposure and assessment of maternal antibodies when indicated may help identify transient forms. Genetic testing may be considered particularly in the presence of goiter, familial recurrence or suspected specific defects in hormone synthesis, because molecular diagnosis may be useful for counseling, prediction of permanence and identification of associated syndromic conditions.
An essential step in diagnostic reasoning is distinguishing permanent from transient forms. This distinction is not based on a single initial finding, but on a combination of information, including biochemical severity, imaging, exposure history and clinical course over time. Scheduled reassessment at an appropriate age, with controlled withdrawal of therapy in selected settings, makes it possible to determine whether replacement treatment remains necessary, thereby avoiding both unnecessary indefinite treatment and harmful premature discontinuation. In cases of suspected central hypothyroidism, the diagnostic evaluation must be extended to the pituitary gland and the other hormonal axes, with priority given to the safety of the corticotropic axis.
In summary, a definitive diagnosis is established through a sequence comprising identification by screening, venous confirmation with FT4 and TSH, early initiation of therapy when indicated, and subsequent etiological and prognostic definition through imaging and targeted investigations. The entire process must be organized to minimize delays and uncertainty, because preventive efficacy depends directly on the speed of correction.
The classification of congenital hypothyroidism is clinically useful because it guides prognosis, follow-up and decisions regarding treatment duration. A first distinction separates permanent forms from transient forms. Permanent forms generally require lifelong replacement therapy and include thyroid dysgenesis and many forms of dyshormonogenesis. Transient forms include conditions in which thyroid function normalizes over time, such as perinatal exposure to excess iodine, maternal antibodies that block the TSH receptor, certain medication effects and some conditions associated with prematurity or neonatal illness. However, classification as “transient” does not eliminate the need for treatment when FT4 is reduced during a critical developmental phase.
A second distinction concerns primary versus central origin. In primary congenital hypothyroidism, the defect is located in the thyroid gland and the biochemical pattern generally shows elevated TSH, whereas in central forms TSH may not be elevated despite reduced FT4. This distinction is crucial because it changes the screening approach and requires consideration of associated pituitary hormone deficiencies, with acute and therapeutic implications. There is also a rarer group of conditions in which the peripheral action of thyroid hormones is altered, although their inclusion within the category of “congenital hypothyroidism” depends on the clinical definition and context and requires specialist interpretation.
Within permanent primary forms, a further classification distinguishes thyroid dysgenesis from dyshormonogenesis. Dysgenesis includes agenesis, ectopia and hypoplasia, often without goiter and with variable severity, but with a higher likelihood of requiring permanent treatment. Dyshormonogenesis includes defects in iodine uptake, organification and coupling, thyroglobulin defects and other abnormalities, often associated with goiter and possible familial recurrence. This distinction may be suggested by imaging and certain biochemical and clinical patterns and may guide the choice of investigations and counseling.
Severity may be conceptualized according to the degree of FT4 reduction and the speed with which FT4 and TSH normalize after treatment is initiated. Forms with very low FT4 require a rapid therapeutic response and closer monitoring during the first weeks because the risk of inadequate cerebral hormone exposure is greater. Mild forms may require a different approach, with particular emphasis on determining permanence and avoiding overtreatment, without underestimating the possibility that even moderate but persistent deficiencies may affect development.
Finally, a practical classification concerns specific clinical settings, including preterm infants, critically ill neonates and neonates with comorbidities. In these cases, test dynamics and the increased likelihood of transient abnormalities or complex interpretation require dedicated pathways, because treatment decisions, the initial dose and the frequency of monitoring must take vulnerability, pharmacokinetics and the risk of fluctuations into account.
The treatment of congenital hypothyroidism consists of the early and continuous administration of levothyroxine, with the objective of rapidly normalizing FT4 and bringing TSH into an appropriate range in primary forms, thereby minimizing the duration of nervous system exposure to hormone deficiency. International recommendations converge on the principle that treatment should be initiated as soon as possible after confirmation, ideally during the earliest weeks of life, because neurocognitive outcomes are strongly dependent on the timing and quality of correction. Treatment must not be delayed while awaiting completion of the etiological assessment, which may be performed subsequently, because the clinical benefit is linked to the speed of intervention.
The initial dose is generally determined according to body weight, with typical ranges of approximately 10-15 micrograms/kg/day in forms requiring rapid correction, adjusting the choice according to biochemical severity and clinical context. Tablets are generally the preferred formulation, administered appropriately to the neonate, because they provide stability and dosing precision. Oral solutions may have a role in selected settings in which adherence or administration is particularly challenging, always with careful monitoring. The initial objective is to achieve a rapid increase in FT4 toward appropriate levels and a progressive reduction in TSH, avoiding both undertreatment, which prolongs exposure to deficiency, and overtreatment, which may cause iatrogenic excess with irritability, tachycardia and accelerated skeletal maturation.
Treatment must be accompanied by a structured monitoring plan during the first weeks, because the response is rapid and small dose adjustments may have a significant impact. The family must receive clear instructions regarding administration, interactions that reduce absorption and the importance of treatment continuity. Even during childhood, factors such as iron or calcium supplements and certain food formulations may interfere with absorption and must be managed consistently with the treatment regimen.
In cases of suspected central hypothyroidism, management must include evaluation of the other pituitary axes, with priority given to the safety of the corticotropic axis. In this setting, initiation of levothyroxine remains important when FT4 is reduced, but clinical management must ensure that any associated deficiencies, particularly adrenocorticotropic hormone deficiency, are identified and treated to prevent acute complications. Management is therefore intrinsically multi-axis and requires specialist coordination.
When the etiology suggests a potentially transient form, treatment is not withheld if the hormonal profile is compatible with clinically significant hypothyroidism, because the risk of hormone deficiency during the earliest stages outweighs the risk of temporarily treating a reversible condition. When plausible, the possibility of transience instead guides the strategy for scheduled reassessment at an appropriate age to determine whether treatment should be permanently discontinued or continued.
Follow-up of congenital hypothyroidism is as important as initial treatment, because protection of neurodevelopment requires not only timely initiation of therapy, but also long-term biochemical stability with adjustments consistent with growth and changes in pharmacokinetics. Monitoring is based on FT4 and TSH, with more frequent testing during the first weeks and months, when the main adjustments are made, and subsequently at regular intervals throughout childhood and adolescence. Interpretation must take into account that the objective is to maintain FT4 within an age-appropriate range while avoiding fluctuations that alternately expose the child to deficiency or excess.
During the first assessments after treatment initiation, attention is focused on the speed with which FT4 reaches desirable levels and on the trajectory of TSH normalization in primary forms. Persistently elevated TSH may indicate an insufficient dose, imperfect adherence, administration errors or interference with absorption. Conversely, excessively high FT4 requires reassessment of the dose to reduce the risk of overtreatment, which during childhood may affect behavior, sleep and skeletal maturation.
Follow-up must integrate clinical and auxological parameters. Linear growth, body weight, pubertal development, skeletal maturation and neuropsychomotor milestones provide essential context for interpreting biochemical findings and identifying potential problems at an early stage. In particular, growth and neurodevelopment are the true endpoints of treatment, whereas laboratory parameters are the controllable proxies. Neurocognitive assessment may be appropriate in high-risk subgroups, such as severe forms, delayed diagnoses or prolonged periods of therapeutic instability.
A specific objective of follow-up is to determine whether the condition is permanent. In cases in which the etiology and clinical course suggest a transient form, reassessment at an appropriate age with controlled withdrawal of levothyroxine should be planned, followed by serial measurements of FT4 and TSH to determine whether treatment can be permanently discontinued. This strategy must be conducted according to rigorous criteria and with adequate surveillance, because inappropriate or unmonitored discontinuation may reintroduce a clinically significant deficiency.
In preterm and critically ill neonates, follow-up requires additional attention because the physiology of the axis and clinical interference increase the risk of fluctuations. In these patients, assessment of the need for treatment, monitoring frequency and decisions regarding reassessment must be individualized. In suspected central forms, follow-up must include surveillance of the other pituitary axes and the possible development of multiple hormone deficiencies, because the endocrine profile may change over time.
In summary, effective follow-up combines biochemical monitoring, growth, development and adherence and maintains a stable long-term replacement trajectory. The quality of monitoring is a direct determinant of outcome, particularly during the first years of life, when the brain is most sensitive to thyroid hormone availability.
The prognosis of congenital hypothyroidism is generally excellent when diagnosis is established early and treatment with levothyroxine is initiated promptly and maintained consistently with appropriate monitoring. In this setting, most children achieve normal growth and neurocognitive development comparable with that of their peers. However, prognosis is not uniform and depends on initial severity, the timing of treatment initiation, the stability of FT4 levels over time and the presence of comorbidities or associated defects. More severe forms, particularly those caused by agenesis or ectopia, require rapid correction and closer follow-up because the risk of inadequate hormone exposure is greater when treatment is underdosed or unstable.
The most important complication in the absence of diagnosis and treatment, or when treatment is delayed or inadequate, is impaired neurodevelopment, with possible cognitive and motor deficits and learning difficulties. This risk is the fundamental rationale for screening and urgent clinical management. Even after treatment has been initiated, prolonged periods of undertreatment during early life may adversely affect certain neurocognitive domains, particularly when FT4 normalization is slow or fluctuations are marked.
A second group of complications is related to overtreatment. During childhood, iatrogenic thyroid hormone excess may cause irritability, sleep disturbances, tachycardia and accelerated skeletal maturation, with potential effects on growth and well-being. This risk should not lead to an excessively cautious approach, because early undertreatment is more dangerous from a neurodevelopmental perspective, but it requires a balanced strategy based on frequent monitoring and careful dose adjustment, particularly during the first months of life.
Etiology-related complications include persistent goiter in dyshormonogenesis, requiring clinical surveillance and, in some cases, specific assessments over time. In certain genetic or syndromic forms, other extrathyroidal manifestations may coexist and influence the overall prognosis, requiring multidisciplinary care pathways. In central forms, prognosis often depends on the presence of associated pituitary hormone deficiencies, particularly corticotropic axis deficiency, which may represent an acute risk if it is not recognized and managed correctly.
Overall, congenital hypothyroidism is a condition in which the most severe complications are highly preventable when management follows a structured approach based on early identification, rapid and appropriate treatment, close monitoring during critical phases and determination of permanence to optimize treatment duration. The quality of the care pathway, rather than the diagnosis itself, determines the long-term outcome.